Related Experiment Video
Updated: May 4, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Pancreatic cancer: advances in medical therapy
Andrew Weickhardt1, Michael Michael
1Peter MacCallum Cancer Centre, Melbourne, Australia. andrewweickhardt@gmail.com.
Abstract:
Progress in the treatment of pancreatic cancer has been notably slow and modest in contrast to other cancers of the GI tract over the last 5 years. Pancreatic cancer still continues to be a devastating illness that is marked by the appearance of early metastatic disease, despite curative surgery and the relative chemoresistance of the disease. However, small incremental benefits have been seen, and point to areas of research and development over the subsequent years. Developments in adjuvant chemotherapy and the use of gemcitabine in combination with other cytotoxic agents or with biological agents have changed clinical practice. Given its poor outlook and the paucity of active therapies, even modest gains can lead to regulatory approval and, therefore, pancreatic cancer represents a common target for pharmaceutical companies. Newer agents are in development with the promise of further refinement in treatment selection based on molecular tumor characteristics.
Insights
Pancreatic cancer treatment shows slow progress, with modest gains from new chemotherapy regimens like gemcitabine. Future research focuses on molecular tumor characteristics for better treatment selection.
Area of Science:
- Oncology
- Gastrointestinal Cancer Research
Background:
- Pancreatic cancer treatment has seen limited progress compared to other GI cancers.
- The disease is characterized by early metastasis and chemoresistance, posing significant challenges.
Purpose of the Study:
- To review recent advancements in pancreatic cancer treatment.
- To highlight areas for future research and development in managing this devastating illness.
Main Methods:
- Analysis of recent clinical practice changes.
- Review of developments in adjuvant chemotherapy and combination therapies.
- Examination of newer agents in development.
Main Results:
- Modest incremental benefits observed in pancreatic cancer treatment.
- Gemcitabine-based chemotherapy regimens have altered clinical practice.
- Newer agents targeting molecular tumor characteristics are under development.
Conclusions:
- Despite challenges, incremental progress in pancreatic cancer therapy is occurring.
- Combination therapies and targeted agents show promise for improved outcomes.
- Personalized treatment selection based on molecular profiling is the future direction.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
01:30Acute Pancreatitis II: Clinical Manifestations and Management
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...